Reimbursement Challenges and Solutions with Molecular Biomarker Testing

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.

Related Videos

September 7, 2018

The Future of Genomics and Targeted Therapies

Dr Andrey Antov muses on the evolution of genomics and how it could potentially impact targeted therapies and cancer care.

January 13, 2015

When to Use Breast Cancer Index

Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the circumstances in which they would use the Breast Cancer IndexSM (BCI) to assist in determining whether to extend the adjuvant therapy of women with breast cancer beyond 5 years.